Dabigatran renal impairment — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardRenal and Hepatic ImpairmentDabigatran renal impairmentGPhC CRA

A woman taking dabigatran has a new eGFR of 26 mL/min/1.73m2. What monitoring is required?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Renal function review because dabigatran exposure increases

This scenario assesses Dabigatran renal impairment in a UK pharmacy practice context. Dabigatran is substantially renally cleared, so renal impairment raises bleeding risk. The best answer is Renal function review because dabigatran exposure increases because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.

Reference: BNF